News Quantified

AXSM – axsome therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory [Yahoo! Finance]

Axsome Therapeutics Highlights Auvelity Momentum, 600-Rep Sales Push, and April 30 ADA PDUFA at Oppenheimer Conf. [Yahoo! Finance]

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics (AXSM) was upgraded by Wolfe Research to "strong-buy".

Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

-1.8%

BEAT

0.6%

MISS

-3.1%

BEAT

1.3%

BEAT

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Murdock Hunter R.

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Maizel Ari

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Pizzie Nick

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: Jacobson Mark L.

Form 4 Axsome Therapeutics, For: Feb 26 Filed by: TABUTEAU HERRIOT

Top News Gainers

12/16 Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder 68.0%

4/27 Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation 25.0%

3/19 Form 4 Axsome Therapeutics, For: Mar 17 Filed by: TABUTEAU HERRIOT 17.1%

6/27 Form 4 Axsome Therapeutics, For: Jun 25 Filed by: Coleman Mark 13.2%

12/3 Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy 11.2%

11/8 Axsome Therapeutics, Inc (AXSM) CEO Herriot Tabuteau on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.7%

10/21 Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy 10.0%

6/12 Axsome Therapeutics Inc (NASDAQ: AXSM) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 9.2%

4/14 Axsome Therapeutics Inc (NASDAQ: AXSM) is now covered by analysts at Cowen Inc. They set an "outperform" rating on the stock. 9.1%

12/18 Axsome Therapeutics Announces Proposed Public Offering of Common Stock 8.4%

Top News Decliners

3/13 Axsome Therapeutics Inc (NASDAQ: AXSM) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -29.5%

8/14 Axsome Therapeutics Inc (NASDAQ: AXSM) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -14.1%

4/27 Form 8-K Axsome Therapeutics, For: Apr 27 -12.8%

3/12 Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update -11.9%

3/30 Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications -11.4%

4/6 Axsome Therapeutics Inc (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock. -10.8%

11/7 Q3/2019 9/30/2019 EPS -0.560 ZacksConsensus -0.410 ActVsEst (0.150) - Miss -10.5%

12/4 Axsome Therapeutics Inc (NASDAQ: AXSM) had its price target raised by analysts at Guggenheim from $65.00 to $48.00. -8.8%

12/1 3 Top Biotech Stocks to Buy in December [The Motley Fool] -8.6%

3/24 Here's Why The Best Is Yet to Come for Axsome Therapeutics [The Motley Fool] -7.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day